# 2026-11691: FDA Gives More Time for Drug Repurposing Ideas

2026-11691, Drug Repurposing for Unmet Medical Needs; Request for Information; Extension of Comment Period, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-06-11, effective 2026-07-13 (as of 2026-06-18).

- Canonical: https://policyrisk.com/federal-register/2026-11691
- As of: 2026-06-18
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-11691
- Title: Drug Repurposing for Unmet Medical Needs; Request for Information; Extension of Comment Period
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 35488
- Published: 2026-06-11
- Effective: 2026-07-13
- Comments close: 2026-07-13
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-18

## In one line

FDA Gives More Time for Drug Repurposing Ideas

## Summary

The FDA is giving everyone more time to share their ideas about using existing drugs to help people with medical needs that aren’t being met. This extension means anyone interested—like patients, doctors, or drug makers—can send in their thoughts until July 13, 2026. It’s a smart move to make sure the FDA hears all voices before moving forward with drug repurposing efforts that could save lives and maybe even save money.

## Abstract

The Food and Drug Administration (FDA, the Agency, or we) is extending the comment period for the notice entitled "Drug Repurposing for Unmet Medical Needs; Request for Information" that appeared in the Federal Register of May 12, 2026 (91 FR 25897). In the notice, FDA requested comments to solicit input on FDA's efforts with respect to drug repurposing to address unmet medical needs. The Agency is taking this action to allow interested persons additional time to submit comments.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-11691 on federalregister.gov](https://www.federalregister.gov/documents/2026/06/11/2026-11691/drug-repurposing-for-unmet-medical-needs-request-for-information-extension-of-comment-period)
- [2026-11691 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-06-11/pdf/2026-11691.pdf)

## Related
- [Previous: 2026-11690, Recommendations on Scale-Up and Postapproval Changes Guidances for Industry; Re…](https://policyrisk.com/federal-register/2026-11690)
- [Next: 2026-11693, Determination Under the Textile and Apparel Commercial Availability Provision o…](https://policyrisk.com/federal-register/2026-11693)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-11691 (as of 2026-06-18).